Pacira BioSciences (PCRX) News Today $25.74 -0.30 (-1.15%) Closing price 02/20/2025 04:00 PM EasternExtended Trading$25.63 -0.11 (-0.41%) As of 02/20/2025 04:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law FirmFebruary 20 at 4:13 PM | prnewswire.comPacira BioSciences, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – PCRXFebruary 20 at 1:27 PM | globenewswire.comPacira to Report 2024 Financial Results on Thursday February 27, 2025February 20 at 8:00 AM | globenewswire.comInvestors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRXFebruary 20 at 5:45 AM | prnewswire.comPACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRXFebruary 19 at 10:05 PM | globenewswire.comPCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitFebruary 19 at 4:00 PM | globenewswire.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PaciraFebruary 19 at 11:34 AM | globenewswire.comPACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRXFebruary 18 at 6:27 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRXFebruary 18 at 6:21 PM | prnewswire.comROSEN, A LEADING LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRXFebruary 18 at 1:24 PM | globenewswire.comLowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmFebruary 18 at 1:11 PM | globenewswire.comLost Money on Pacira BioSciences, Inc.(PCRX)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyFebruary 18 at 5:45 AM | prnewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Rating of "Hold" by BrokeragesFebruary 18 at 2:47 AM | americanbankingnews.comPCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud LawsuitFebruary 17, 2025 | gurufocus.comPCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud LawsuitFebruary 17, 2025 | prnewswire.comZacks Research Issues Pessimistic Forecast for PCRX EarningsPacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Stock analysts at Zacks Research dropped their FY2024 earnings per share (EPS) estimates for Pacira BioSciences in a note issued to investors on Tuesday, February 11th. Zacks Research analyst R. Department now forecasts that the company willFebruary 15, 2025 | marketbeat.comWhat is Zacks Research's Estimate for PCRX FY2024 Earnings?February 15, 2025 | americanbankingnews.comLowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmFebruary 14, 2025 | globenewswire.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRXFebruary 14, 2025 | globenewswire.comPacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRXFebruary 14, 2025 | prnewswire.comPCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitFebruary 13, 2025 | globenewswire.comContact Levi & Korsinsky by March 14, 2025 Deadline to Join Class Action Against Pacira BioSciences, Inc. (PCRX)February 13, 2025 | globenewswire.comZacks Research Issues Positive Forecast for PCRX EarningsPacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Analysts at Zacks Research increased their Q4 2026 earnings per share estimates for Pacira BioSciences in a research report issued on Tuesday, February 11th. Zacks Research analyst R. Department now forecasts that the company will post earninFebruary 13, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of "Hold" by BrokeragesPacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has received a consensus recommendation of "Hold" from the nine research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold ratingFebruary 13, 2025 | marketbeat.comThe Gross Law Firm Reminds Pacira BioSciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRXFebruary 13, 2025 | prnewswire.comPACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRXFebruary 12, 2025 | globenewswire.comPCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud LawsuitFebruary 12, 2025 | prnewswire.comClass Action Filed Against Pacira BioSciences, Inc. (PCRX) - March 14, 2025 Deadline to Join – Contact The Gross Law FirmFebruary 12, 2025 | globenewswire.comEmpowered Funds LLC Buys 11,149 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Empowered Funds LLC grew its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 5.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 229,485 shares of the company's stock after acquiring anFebruary 12, 2025 | marketbeat.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRXFebruary 11, 2025 | globenewswire.comPACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. – PCRXFebruary 11, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRXFebruary 11, 2025 | prnewswire.comLevi & Korsinsky Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRXFebruary 11, 2025 | prnewswire.comShareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn MoreFebruary 10, 2025 | globenewswire.comPacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law ...February 10, 2025 | gurufocus.comPacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRXFebruary 10, 2025 | prnewswire.comROSEN, NATIONAL INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PCRXFebruary 9, 2025 | investing.comJanney Montgomery Scott LLC Sells 23,313 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Janney Montgomery Scott LLC reduced its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 44.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 29,395 shares of the company's stock after sellinFebruary 9, 2025 | marketbeat.comROSEN, LEADING INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. ...February 8, 2025 | gurufocus.comROSEN, LEADING INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRXFebruary 8, 2025 | globenewswire.comPACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRXFebruary 7, 2025 | prnewswire.comPCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitFebruary 7, 2025 | globenewswire.comLowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmFebruary 7, 2025 | globenewswire.comShareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn MoreFebruary 7, 2025 | globenewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PaciraFebruary 7, 2025 | prnewswire.comShareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreFebruary 7, 2025 | prnewswire.comPCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud LawsuitFebruary 6, 2025 | prnewswire.comClass Action Filed Against Pacira BioSciences, Inc. (PCRX) Seeking Recovery for Investors – Contact The Gross Law FirmFebruary 6, 2025 | globenewswire.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 6, 2025 | globenewswire.comThe Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming DeadlineFebruary 6, 2025 | prnewswire.com Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address PCRX Media Mentions By Week PCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCRX News Sentiment▼0.050.60▲Average Medical News Sentiment PCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCRX Articles This Week▼257▲PCRX Articles Average Week Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Perrigo News Today Supernus Pharmaceuticals News Today Omeros News Today Nektar Therapeutics News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Eli Lilly and Company News Today Johnson & Johnson News Today AbbVie News Today Merck & Co., Inc. News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCRX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
